1 active not recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Array Biopharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 + nivolumab+ipilimumab, Phase II ARRY-614 + nivolumab - Renal Cell Carcinoma, Melanoma | Phase 1 / Phase 2 | Active not recruiting | Dan Zandberg | 70 | 2020-06-11 | 2025-11-06 |
Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Melanoma (1) · Squamous Cell Carcinoma of Head and Neck (1)
Nivolumab (1)
United States (1)
Dan Zandberg, MD (1)